Tuesday, November 13, 2018

8-week Maviret HCV genotype 1-6 & compensated cirrhosis:The EXPEDITION-8 Study

Meeting Coverage @ infohep Keith Alcorn / 14 November 2018
An 8-week course of the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C in people with compensated cirrhosis, across a wide range of genotypes, Robert S. Brown of Weill Cornell Medical College reported at the AASLD Liver Meeting in San Francisco this week. Maviret is a highly effective combination of an HCV protease inhibitor (glecaprevir) and an NS5A inhibitor (pibrentasvir) that has been shown to cure hepatitis C in 98% of people without cirrhosis after eight weeks of treatment. A previous study showed that a 12-week course of the combination cured hepatitis C in 99% of people with compensated cirrhosis. The EXPEDITION-8 study was designed to test whether an 8-week treatment course was as effective in previously untreated people with compensated cirrhosis as the rate of cure achieved in the previous 12-week study.
High SVR12 rate suggests 8-week treatment could be used for this population
Read more: https://www.medpagetoday.com/meetingcoverage/aasld/76333
Coverage @ MedPage Today Twitter @medpagetoday

Recommended Coverage
View updates on this blog (LINK), recommended coverage (LINK).

Presented at the AASLD: The Liver Meeting®
Preliminary efficacy & safety of 8-week GLE/PIB in patients with #HCV genotype 1-6 infection & compensated cirrhosis: The EXPEDITION-8 Study 


Shared via @HenryEChang on twitter.

No comments:

Post a Comment